Microbiome startup Finch Therapeutics lands first big partnership with Japanese firm Takeda to work on "FIN-524", a preclinical program for IBD
Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz
Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor. That incident both intrigued
Join in on the conversation with Simon when you subscribe to Better Business Development.